Jasper Therapeutics, Inc.
JSPR
$1.65
$0.074.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.32% | 25.72% | 20.22% | 19.57% | 6.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.26% | 38.00% | 18.55% | 10.71% | 5.85% |
| Operating Income | -33.26% | -38.00% | -18.55% | -10.71% | -5.85% |
| Income Before Tax | -43.27% | -45.62% | -23.23% | -10.55% | -3.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.27% | -45.62% | -23.23% | -10.55% | -3.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.27% | -45.62% | -23.23% | -10.55% | -3.98% |
| EBIT | -33.26% | -38.00% | -18.55% | -10.71% | -5.85% |
| EBITDA | -34.55% | -38.39% | -18.50% | -10.50% | -5.46% |
| EPS Basic | -24.38% | -17.96% | 6.29% | 21.47% | 42.80% |
| Normalized Basic EPS | -22.02% | -17.21% | 7.47% | 21.27% | 42.81% |
| EPS Diluted | -24.38% | -17.96% | 6.29% | 21.47% | 42.80% |
| Normalized Diluted EPS | -22.02% | -17.21% | 7.47% | 21.27% | 42.81% |
| Average Basic Shares Outstanding | 14.04% | 19.92% | 29.70% | 39.80% | 58.29% |
| Average Diluted Shares Outstanding | 14.04% | 19.92% | 29.70% | 39.80% | 58.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |